Hearing Loss - Healing Genes

Hearing Loss

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss

A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss

Phase 1/2

Doctors at Novartis study centers in KA and OR seek patients with unilateral or bilateral severe-to-profound hearing loss to trial an investigational gene therapy, called CGF166, that uses a viral shell to deliver a gene that can prompt growth of inner-ear hair filaments and possibly improve hearing. The study would require a single intra-labyrinthine (inner-ear) infusion of the drug, then 24 months of follow up to track any negative reactions and hearing improvements.


  • Up to 18 to 75 years of age
  • Have severe-to-profound bilateral hearing loss or unilateral hearing loss with intact vestibular function in the nonoperative ear. Non-fluctuating severe-to-profound hearing loss is required for the study ear and is defined as:
    • PTA within 10 dB of the PTA obtained at least 11 months previously
    • Word recognition within 20% of previous test at least 11 months previously
  • Meet residual hearing criteria and vestibular function in the ear that will be studied


  1. Prescreening to confirm eligibility of the patient to participate.
  2. Single intra-labyrinthine (inner-ear) infusion of the drug to a single “study ear”.
  3. Follow up will continue for up to 2 years.

The study sites are in Kansas City, KA, and Portland, OR. To learn where, contact the trial coordinator below.

Novartis Pharmaceuticals  |  1-888-669-6682  |  [email protected]
Novartis Pharmaceuticals
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader